Summary of ASH 2019

Jack Aiello |

Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early Tuesday morning describing a phase III trial called Candor for relapsed/refractory multiple myeloma patients (RRMM), comparing (Kyprolis) carfilzomib and dexamethasone with or without Darzalex (daratumumab). The abstract #LBA-6 showed that the addition of dara decreased the risk […]

It Takes a Village

Sheri Baker |

I’ll admit I was a little starstruck at ASH. The top myeloma specialists were gathered in one place, walking the same corridors as me…sitting in the same abstract presentations as me.  And having some of the same questions as I did about the research being presented. I was used to being at patient seminars or my […]

Monoclonal Antibodies Take ASH by Storm

Linda Huguelet |

Monoclonal antibodies are becoming the backbone of treatments for relapsed and refractory patients, but they are also making their way into the front-line setting for newly diagnosed patients. The first official day of the American Society of Hematology (ASH) Annual Conference was filled presentations, posters, and exhibits touting the effectiveness of this drug class. I would […]

Selinexor at ASH 2019

Jim Omel |

Relapsed/Refractory Multiple Myeloma (RRMM) patients often face difficult and diminishing treatment options. We have effective immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs,) and monoclonal antibodies ( (MoAbs), but what do patients do when these drugs lose effect? New immunotherapies such as CAR-T and BiTEs help patients late in their disease if they meet inclusion criteria. Also, clinical trials […]

Pandora’s Box of Myeloma Treatment

Yelak Biru |

Over the last two decades, the treatment landscape for multiple myeloma has changed significantly. In the 1990s there were no approved novel therapies for myeloma. Since 2003 there have been over 11 treatments approved for the treatment of myeloma (in the United States). With those approvals, the treatment algorithms have become very complex. After the […]